UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10−Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: March 31, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to _____________

 

Commission File Number: 000-31377

 

REFLECT SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)

 

Utah   87-0642556
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

1266 South 1380 West, Orem, UT   84058
(Address of principal executive offices)   (Zip Code)

 

(801) 226-4100
(Registrant’s telephone number, including area code)

 

N/A
(Former name, former address and formal fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
    Emerging growth company

 

 
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of May 11, 2023, there were 85,214,086 common shares of the registrant issued and outstanding. 

 

 

 

 

 
 

 

 

REFLECT SCIENTIFIC, INC.

 

Quarterly Report on Form 10-Q

 Period Ended March 31, 2023

 

 

TABLE OF CONTENTS

 

PART I

FINANCIAL INFORMATION

 

Item 1: Financial Statements 2
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 3: Quantitative and Qualitative Disclosure about Market Risk 15
Item 4: Controls and Procedures 15

 

PART II

OTHER INFORMATION

 

Item 1: Legal Proceedings 15
Item 1A. Risk Factors 15
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 15
Item 3: Defaults Upon Senior Securities 15
Item 4: Mine Safety Disclosure 16
Item 5: Other Information 16
Item 6: Exhibits 16

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1 

 

PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

 

REFLECT SCIENTIFIC, INC.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

    Page
     
Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022   3
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022 (Unaudited)   4
Condensed Consolidated Statements of Stockholders’ Equity for the Three Ended March 31, 2023 and 2022 (Unaudited)   5
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022 (Unaudited)   6
Notes to Condensed Consolidated Financial Statements (Unaudited)   7

 

 

2 

 

 

  REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

    March 31,
2023
    December 31, 2022  
    (Unaudited)        
ASSETS            
             
Current Assets            
Cash and cash equivalents   $ 1,199,069     $ 1,381,927  
Accounts receivable, net     108,368       129,329  
Inventories, net     850,620       797,352  
Prepaid expenses and other current assets     6,000       20,221  
Total Current Assets     2,164,057       2,328,829  
                 
Operating lease right-of-use assets     39,736       54,265  
Goodwill     60,000       60,000  
Other long-term assets     3,100       3,100  
TOTAL ASSETS   $ 2,266,893     $ 2,446,194  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
                 
Current Liabilities                
Accounts payable and accrued expenses   $ 68,196     $ 78,969  
Customer deposits     810       13,230  
Current portion of operating lease liabilities     42,249       57,393  
Total Current Liabilities     111,255       149,592  
                 
TOTAL LIABILITIES     111,255       149,592  
                 
Stockholders' Equity                
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; none issued and outstanding as of March 31, 2023 and December 31, 2022     -       -  
Common shares, $0.01 par value, 100,000,000 shares authorized; 85,214,086 shares issued and outstanding as of March 31, 2023 and December 31, 2022     852,140       852,140  
Additional paid-in capital     20,259,056       20,252,181  
Accumulated deficit     (18,955,558 )     (18,807,719 )
TOTAL STOCKHOLDERS’ EQUITY     2,155,638       2,296,602  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 2,266,893     $ 2,446,194  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3 

 

 

 

 REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

Three Months Ended

March 31,

 
    2023     2022  
Revenues   $ 241,127     $ 753,576  
Cost of goods sold     113,633       234,289  
Gross profit     127,494       519,287  
                 
Operating Expenses                
Salaries and wages     162,275       170,279  
General and administrative     106,992       117,178  
Research and development     6,066       25,325  
Total Operating Expenses     275,333       312,782  
                 
INCOME (LOSS) FROM OPERATIONS     (147,839 )     206,505  
                 
NET INCOME (LOSS) BEFORE INCOME TAXES     (147,839 )     206,505  
INCOME TAX BENEFIT (EXPENSE)     -       -  
NET INCOME (LOSS)   $ (147,839 )   $ 206,505  
                 
Earnings (loss) per common share                
Basic   $ (0.00 )   $ 0.00  
Diluted   $ (0.00 )   $ 0.00  
                 
Weighted average shares outstanding                
Basic     85,214,086       84,989,086  
Diluted     85,214,086       85,739,086  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

4 

 

 

 

REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

Three Months Ended March 31, 2023

 

    Common Shares     Additional
Paid-In
    Accumulated     Total
Stockholders’

 
    Shares     Amount     Capital     Deficit     Equity  
Balance at December 31, 2022     85,214,086     $ 852,140     $ 20,252,181     $ (18,807,719 )   $ 2,296,602  
Stock-based compensation     -       -       6,875       -       6,875  
Net loss     -       -       -       (147,839 )     (147,839 )
Balance at March 31, 2023     85,214,086     $ 852,140     $ 20,259,056     $ (18,955,558 )   $ 2,155,638  

 

 

 Three Months Ended March 31, 2022

 

    Common Shares     Additional
Paid-In
    Accumulated     Total
Stockholders’

 
    Shares     Amount     Capital     Deficit     Equity  
Balance at December 31, 2021     84,989,086     $ 849,890     $ 20,226,931     $ (18,897,115 )   $ 2,179,706  
Stock-based compensation     -       -       12,844       -       12,844  
Net income     -       -       -       206,505       206,505  
Balance at March 31, 2022     84,989,086     $ 849,890     $ 20,239,775     $ (18,690,610 )   $ 2,399,055  

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

5 

 

 

REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS

(UNAUDITED)

 

 

    Three Months Ended
March 31,
 
    2023     2022  
CASH FLOWS FROM OPERATING ACTIVITIES            
Net income (loss)   $ (147,839 )   $ 206,505  
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:                
Stock-based compensation     6,875       12,844  
Amortization of right-of-use assets     14,529       13,871  
Changes in operating assets and liabilities:                
Accounts receivable     20,961       (57,680 )
Inventories     (53,268 )     (71,121 )
Prepaid expenses and other current assets     14,221       27,796  
Accounts payable and accrued expenses     (10,773 )     16,609  
Customer deposits     (12,420 )     (29,563 )
Operating lease liabilities     (15,144 )     (13,652 )
Net cash (used in) provided by operating activities     (182,858 )     105,609  
                 
CASH FLOWS FROM INVESTING ACTIVITIES                
Net cash provided by investing activities     -       -  
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Net cash provided by financing activities     -       -  
                 
NET CHANGE IN CASH AND CASH EQUIVALENTS     (182,858 )     105,609  
                 
CASH AND CASH EQUIVALENTS                
Beginning of the period     1,381,927       1,473,924  
End of the period   $ 1,199,069     $ 1,579,533  
                 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION                
Cash paid for interest   $ -     $ -  
Cash paid for income taxes   $ -     $ -  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6 

 

 

REFLECT SCIENTIFIC, INC.

Notes to Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

 

 

NOTE 1—BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements of Reflect Scientific, Inc. (the “Company,” “we,” “us,” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all information and footnotes required by GAAP for complete financial statements. The December 31, 2022 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 31, 2023. The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

 

NOTE 2—RECENT ACCOUNTING PRONOUNCEMENTS

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). The Company has evaluated all recent accounting pronouncements and determined that the adoption of pronouncements applicable to the Company has not had or is not expected to have a material impact on the Company's condensed consolidated financial statements.

 

7 

 

 NOTE 3—DISAGGREGATION OF REVENUES

 

Our revenue is disaggregated based on product category and geographical region. We recognize revenue from the sale of scientific equipment for the life sciences and manufacturing industries. Our products range from non-mechanical Cyrometrix freezers, chillers, and original equipment manufacturer (“OEM”) value-added products and components for the life sciences industry.

 

The Company’s revenues for the three months ended March 31, 2023 and 2022 are disaggregated as follows:

 

    Three Months Ended March 31, 2023
    United States     International     Total  
Revenues                  
Freezers and chillers   $ 45,250     $ -     $ 45,250  
OEM and other     127,880       67,997       195,877  
Total Revenues   $ 173,130     $ 67,997     $ 241,127  

 

 

    Three Months Ended March 31, 2022
    United States     International     Total  
Revenues                  
Freezers and chillers   $ 348,458     $ 153,236     $ 501,694  
OEM and other     172,443       79,439       251,882  
Total Revenues   $ 520,901     $ 232,675     $ 753,576  

 

NOTE 4—INVENTORIES

 

Inventories at March 31, 2023 and December 31, 2022 consisted of the following:

 

    March 31,
2023
    December 31,
2022
 
Finished goods   $ 363,010     $ 376,334  
Raw materials     593,654       527,062  
Total inventories     956,664       903,396  
Less reserve for obsolescence     (106,044 )     (106,044 )
Total inventories, net   $ 850,620     $ 797,352  

 

Inventory balances are composed of finished goods. Raw materials and work in process inventory are immaterial to the condensed consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8 

 

 

NOTE 5—LEASES

 

The following was included in our condensed consolidated balance sheet at March 31, 2023 and December 31, 2022:

 

    March 31,
2023
    December 31,
2022
 
Operating lease right-of-use assets   $ 39,736     $ 54,265  
                 
Lease liabilities, current portion     42,249       57,393  
Lease liabilities, long-term     -       -  
Total operating lease liabilities   $ 42,249     $ 57,393  
                 
Weighted-average remaining lease term (months)     8       11  
Weighted average discount rate     5.25%       5.25%  

 

Total lease expense for the three months ended March 31, 2023 and 2022 is as follows:

 

    Three Months Ended       March 31,
    2023     2022  
Operating lease expense   $ 15,216     $ 15,216  
Variable lease expense     4,437       2,393  
Total lease expense   $ 19,653     $ 17,609  

 

As of March 31, 2023, maturities of operating lease liabilities were as follows:

 

Year Ending December 31,   Amount
2023 – remaining   $ 43,089  
Less: imputed interest     (840 )
Total operating lease liabilities   $ 42,249  

  

NOTE 6—STOCKHOLDERS’ EQUITY

 

Common Stock

 

As of March 31, 2023, the Company was authorized to issue 100,000,000 common shares. As of March 31, 2023 and December 31, 2022, the Company had 85,214,086 common shares issued and outstanding.

 

Restricted Stock Awards

 

Below is a table summarizing the changes in restricted stock awards outstanding during the three months ended March 31, 2023: 

 

    Restricted Stock Awards     Weighted-
Average
Exercise Price
 
Outstanding at December 31, 2022     450,000     $ 0.11  
Granted     -       -  
Vested     -       -  
Forfeited     -       -  
Outstanding at March 31, 2023     450,000     $ 0.11  

  

 

9 

 

Stock-based compensation expense of $6,875 and $12,844 was recorded during the three months ended March 31, 2023 and 2022, respectively.

 

As of March 31, 2023, the remaining unrecognized stock-based compensation expense related to non-vested restricted stock awards is $48,125 and is expected to be recognized over 1.75 years.

 

NOTE 7—EARNINGS (LOSS) PER SHARE

 

The computation of weighted average shares outstanding and the basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 consisted of the following:

 

   

Three Months Ended

March 31,

    2023     2022  
Net income (loss)   $ (147,839 )   $ 206,505  
Weighted average shares outstanding     85,214,086       84,989,086  
Basic earnings (loss) per share   $ (0.00 )   $ 0.00  
                 
Weighted average shares outstanding     85,214,086       84,989,086  
Effect on dilutive stock awards     -       750,000  
Total potential shares outstanding     85,214,086       85,739,086  
Diluted earnings (loss) per share   $ (0.00 )   $ 0.00  

 

For the three months ended March 31, 2023,there were 450,000 common share equivalents excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10 

 

 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following management’s discussion and analysis of financial condition and results of operations provides information that management believes is relevant to an assessment and understanding of our plans and financial condition. The following financial information is derived from our financial statements and should be read in conjunction with such financial statements and notes thereto set forth elsewhere herein.

 

Use of Terms

 

Except as otherwise indicated by the context and for the purposes of this report only, references in this report to “we,” “us,” “our” and the “Company” refer to Reflect Scientific, Inc., and its consolidated subsidiaries.

 

Special Note Regarding Forward Looking Statements

 

This report contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

 

  Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest;

 

  Changes in U.S., global or regional economic conditions;

 

  Changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments;

 

  Increased competitive pressures, both domestically and internationally;

 

  Legal and regulatory developments, such as regulatory actions affecting environmental activities;

 

  The imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls;

 

  Adverse weather conditions or natural disasters, such as hurricanes and earthquakes, labor disputes, which may lead to increased costs or disruption of operations.

 

 

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.

 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

11 

 

 

 

The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

 

Overview

 

Reflect Scientific is engaged in the manufacture and distribution of innovative products targeted at the life science market. Our customers include hospitals, diagnostic laboratories, pharmaceutical and biotech companies, cold chain management, universities, government and private sector research facilities, chemical and industrial companies.

 

Our goal is to provide our customers with the best solution for their needs. This philosophy extends into our business strategies and acquisition plans. Through a series of strategic acquisitions, we acquired technology that has enabled us to expand our line of products to align with, and capitalize on, market needs. Our growing product portfolio includes ultra-low temperature freezers, blast freezers, solvent chillers and refrigerated transportation in addition to supplying OEM products to the life sciences industry.

 

Our Cryometrix brand ultra-low temperature and blast freezers innovative design enables our customers to save substantially on energy costs related to cryogenic storage. Ultra-low temperature freezers are used worldwide for the storage of vaccines, DNA, RNA, proteins and many other biological and chemical substances. There is a growing need for energy efficient, reliable ultra-low temperature storage units. Our Cryometrix freezers are targeted to this growing market and we have had tremendous success in blood storage and pharmaceutical manufacturing applications. The application of this technology for use in refrigerated trailers (commonly called “reefers”) used to transport goods which need to be maintained in a cold environment significantly broadens the market for this technology. The utilization of this technology in reefers eliminates the current method of cooling, which uses engines run on hydrocarbon fuels. The Cryometrix technology is pollutant free and is more efficient and cost effective than the technologies currently used. Reflect Scientific has added a new product line of solvent chillers. Solvent chillers are used in natural products extraction for optimizing product yield and purity.

 

Recent Developments

 

None.

 

Impact of Coronavirus Pandemic

 

Starting in late 2019, a novel strain of the coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United States. Most states and cities have at various times instituted quarantines, restrictions on travel, “stay at home” rules, social distancing measures and restrictions on the types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. At this time, there continues to be significant volatility and uncertainty relating to the full extent to which the COVID-19 pandemic and the various responses to it will impact our business, operations and financial results.

 

The pandemic has impacted and may continue to impact some suppliers and manufacturers on some of our products. As a result, we have faced and may continue to face longer supply chain lead-times and higher logistics costs. Additionally, costs for raw materials have also started to increase due to availability, which could negatively affect its business and financial results.

 

The extent to which the pandemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted as of the date of this report, including the effectiveness of vaccines and other treatments for COVID-19, and other new information that may emerge concerning the severity of the pandemic and steps taken to contain the pandemic or treat its impact, among others. Nevertheless, the pandemic and the current financial, economic and capital markets environment, and future developments in the global supply chain and other areas present material uncertainty and risk with respect to our performance, financial condition, results of operations and cash flows.

12 

 

 

Critical Accounting Policies and Estimates

 

The preparation of the unaudited condensed consolidated financial statements requires our management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

 

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 31, 2023.

 

During the three months ended March 31, 2023, there were no significant changes in our accounting policies and estimates.

 

Results of Operations

 

Comparison of the Three Months Ended March 31, 2023 and 2022

 

The following table sets forth key components of our results of operations during the three months ended March 31, 2023 and 2022, both in dollars and as a percentage of our revenues.

 

 

    Three Months Ended March 31,  
    2023     2022  
    Amount    

% of

Revenues

    Amount    

% of

Revenues

 
Revenues   $ 241,127       100.0 %   $ 753,576       100.0 %
Cost of goods sold     113,633       47.1 %     234,289       31.1 %
Gross profit     127,494       52.9 %     519,287       68.9 %
                                 
Operating expenses                                
Salaries and wages     162,275       67.3 %     170,279       22.6 %
General and administrative     106,992       44.4 %     117,178       15.5 %
Research and development     6,066       2.5 %     25,325       3.4 %
Total operating expenses     275,333       114.2     312,782       41.5
                                 
Income (loss) from operations     (147,839 )     (61.3 )%     206,505       27.4 %
                                 
Net income before income taxes     (147,839 )     (61.3 )%     206,505       27.4 %
                                 
Income tax expense     -       - %     -       - %
                                 
Net income   $ (147,839 )     (61.3 )%   $ 206,505       27.4 %

 

Revenues. Revenues decreased by $512,449, or 68.0%, to $241,127 for the three months ended March 31, 2023 from $753,576 for the three months ended March 31, 2022. The change was primarily due to a significant decrease in freezer and chiller sales and ongoing supply chain delays with manufacturers.

 

13 

 

Cost of goods sold. Cost of good sold decreased by $120,656, or 51.5%, to $113,633 for the three months ended March 31, 2023 from $234,289 for the three months ended March 31, 2022. The change was primarily due to decreased freezer and chillers sales.

 

Gross profit. Our gross profit as a percentage of sales decreased to 52.9% for the three months ended March 31, 2023, compared to 68.9% for the three months ended March 31, 2022. The change in gross profit percentage was primarily due to the decrease in freezer and chiller sales (freezer and chillers have higher margins than other products) and increased product costs.

 

Salaries and wages. Salaries and wages decreased by $8,004, or 4.7%, to $162,275 for the three months ended March 31, 2023 from $170,279 for the three months ended March 31, 2022. Such decrease was primarily due to decreased headcount.

 

General and administrative. General and administrative expenses decreased by $10,186, or 8.7%, to $106,992 for the three months ended March 31, 2023 from $117,178 for the three months ended March 31, 2022. The lower expense level was not the result of significant savings in any one expense category but is, rather, the cumulative result of small savings in numerous expenses, offset by increased public filing and insurance costs.

 

Research and development. Research and development expenses decreased by $19,259, or 76.0%, to $6,066 for the three months ended March 31, 2023 from $25,325 for the three months ended March 31, 2022. The change was primarily a result of decreased enhancements to the ultra-cold CBD oil chiller during the quarter.

 

Net income (loss). As a result of the cumulative effect of the factors described above, our net loss was $147,839 for the three months ended March 31, 2023, as compared to net income of $206,505 for the three months ended March 31, 2022. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

 

Liquidity and Capital Resources

 

As of March 31, 2023 and December 31, 2022, our current assets exceeded current liabilities by $2,052,802 and $2,179,237, respectively, and we had cash and cash equivalents of $1,199,069 and $1,381,927, respectively. To date, we have financed our operations primarily through revenue generated from operations, cash proceeds from financing activities, borrowings, and equity contributions by our shareholders.

 

Summary of Cash Flow

 

The following table provides detailed information about our net cash flow for the period indicated:

 

    Three Months Ended
March 31,
 
    2023     2022  
Net cash (used in) provided by operating activities   $ (182,858 )   $ 105,609  
Net cash provided by investing activities     -       -  
Net cash provided by financing activities     -       -  
Net change in cash and cash equivalents     (182,858 )     105,609  
Cash and cash equivalents at beginning of period     1,381,927       1,473,924  
Cash and cash equivalents at end of period   $ 1,199,069     $ 1,579,533  

 

Net cash used in operating activities was $182,858 for the three months ended March 31, 2023, as compared to net cash provided by operating activities of $105,609 for the three months ended March 31, 2022. Significant factors affecting operating cash flows was primarily a result of increased accounts payable and accrued expense payments and decreased net income during the three months ended March 31, 2023.

 

We continue working to enhance our on-line ordering system to increase sales, develop the market for our ultra-low temperature freezers, work with current vendors to obtain more favorable pricing, and locate new vendors to provide opportunities to further reduce our cost of goods.

14 

 

 

We will continue to focus our efforts on our core business activities while pursuing capital resources and evaluating potential future acquisitions which fit within and enhance our core business.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management, including our chief executive officer and chief principal officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of March 31, 2023. Based upon, and as of the date of this evaluation, our chief executive officer and principal financial officer determined that there have been no changes in our internal controls over financial reporting as of March 31, 2023 to the material weaknesses described in Item 9A “Controls and Procedures” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, our disclosure controls and procedures were not effective.

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these, or other matters, may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

15 

 

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

ITEM 6. Exhibits

 

(a)     Exhibits.

 

 

Exhibit No. Title of Document Location if other than attached hereto
3.1 Articles of Incorporation 10-SB Registration Statement*
3.2 Articles of Amendment to Articles of Incorporation 10-SB Registration Statement*
3.3 By-Laws 10-SB Registration Statement*
3.4 Articles of Amendment to Articles of Incorporation 8-K Current Report dated December 31, 2003*
3.5 Articles of Amendment to Articles of Incorporation 8-K Current Report dated December 31, 2003*
3.6 Articles of Amendment September 30, 2004 10-QSB Quarterly Report*
3.7 By-Laws Amendment September 30, 2004 10-QSB Quarterly Report*
4.1 Debenture 8-K Current Report dated June 29, 2007*
4.2 Form of Purchasers Warrant 8-K Current Report dated June 29, 2007*
4.3 Registration Rights Agreement 8-K Current Report dated June 29, 2007*
4.4 Form of Placement Agreement 8-K Current Report dated June 29, 2007*
10.1 Securities Purchase Agreement 8-K Current Report dated June 29, 2007*
10.2 Placement Agent Agreement 8-K Current Report dated June 29, 2007*
14 Code of Ethics December 31, 2003 10-KSB Annual Report*
21 Subsidiaries of the Company December 31, 2004 10-KSB Annual Report*

 

Exhibit No. Title of Document Location if other than attached hereto
31.1 302 Certification of Kim Boyce  
31.2 302 Certification of Keith Merrell  
32 906 Certification  

 

Exhibits

 

Additional Exhibits Incorporated by Reference

     
* Reflect California Reorganization 8-K Current Report dated December 31, 2003
* JMST Acquisition 8-K Current Report dated April 4, 2006
* Cryomastor Reorganization 8-K Current Report dated September 27, 2006
* Image Labs Merger Agreement Signing 8-K Current Report dated November 15, 2006
* All Temp Merger Agreement Signing 8-K Current Report dated November 17, 2006
* All Temp Merger Agreement Closing 8-KA Current Report dated November 17, 2006
* Image Labs Merger Agreement Closing 8-KA Current Report dated November 15, 2006

 

* Previously filed and incorporated by reference.

16 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Reflect Scientific, Inc.

(Registrant)

 

 

Date: May 11, 2023                                                        By: /s/ Kim Boyce

Kim Boyce, CEO, President and Director

 

Date: May 11, 2023                                                         By: /s/ Tom Tait

Tom Tait, Vice President and Director

 

Date: May 11, 2023                                                         By: /s/ Kim Boyce

Kim Boyce, CFO, Principal Financial Officer

 

 

 

17 

 

 

 

 

 

 

 

 

 

 

 

 

10-Q --12-31 false Q1 0001103090 None 0001103090 2023-01-01 2023-03-31 0001103090 2023-05-11 0001103090 2023-03-31 0001103090 2022-12-31 0001103090 2022-01-01 2022-03-31 0001103090 us-gaap:CommonStockMember 2022-12-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001103090 us-gaap:RetainedEarningsMember 2022-12-31 0001103090 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001103090 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001103090 us-gaap:CommonStockMember 2023-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001103090 us-gaap:RetainedEarningsMember 2023-03-31 0001103090 us-gaap:CommonStockMember 2021-12-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001103090 us-gaap:RetainedEarningsMember 2021-12-31 0001103090 2021-12-31 0001103090 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001103090 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001103090 us-gaap:CommonStockMember 2022-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001103090 us-gaap:RetainedEarningsMember 2022-03-31 0001103090 2022-03-31 0001103090 country:US 2023-01-01 2023-03-31 0001103090 rscf:InternationalMember 2023-01-01 2023-03-31 0001103090 country:US 2022-01-01 2022-03-31 0001103090 rscf:InternationalMember 2022-01-01 2022-03-31 0001103090 rscf:OperatingLeaseLiabilitiesMember 2023-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure